Mirum Pharamceuticals (MIRM) Licensing Deal Bodes Well for Upcoming PDUFA Date - Piper Sandler
Tweet Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $77.00 price target on Mirum Pharamceuticals (NASDAQ: MIRM) noting the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
